ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, GenesisX™. GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for ...

Core Insights - Stereotaxis has successfully launched its Genesis Robotic Magnetic Navigation System at Erasmus University Medical Center in Rotterdam, marking a significant advancement in surgical robotics for minimally invasive endovascular interventions [1][2]. Company Overview - Stereotaxis is a pioneer in surgical robotics, focusing on minimally invasive endovascular interventions, with a mission to develop robotic systems and solutions that enhance patient care and operational efficiency in interventional laboratories [3]. Technological Advancements - The Genesis System represents the latest in Robotic Magnetic Navigation technology, which enhances precision and safety in cardiac ablation procedures for treating arrhythmias [2]. - The combination of the Genesis system and the MAGiC Catheter has shown synergistic improvements in robotic magnetic navigation, which is crucial for providing optimal care to arrhythmia patients, including those with complex conditions [2]. Clinical Impact - Erasmus MC has performed over 4,500 procedures using Stereotaxis technology, demonstrating the effectiveness and reliability of robotic magnetic navigation in complex arrhythmia treatments [2]. - Arrhythmias affect tens of millions globally, and untreated cases can lead to severe health risks such as stroke and heart failure, highlighting the importance of advanced treatment options like those offered by Stereotaxis [2].